Browse > Article
http://dx.doi.org/10.6114/jkood.2018.31.4.022

Literature Review on Herbal Medicine Treatment of Psoriasis Based on Chronic Low-grade Inflammation Theory  

Jeung, Chang-Woon (Chung-yeon Medical Institute)
Jeon, Sun-Woo (Chung-yeon Medical Institute)
Jo, Hee-Geun (Chung-yeon Medical Institute)
Publication Information
The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology / v.31, no.4, 2018 , pp. 22-30 More about this Journal
Abstract
Objectives : The aim of this study is to investigate the relationship between chronic low grade inflammation theory, psoriasis, and herbal medicine. Methods : We reviewed recent studies on the relationship between chronic low-grade inflammation, psoriasis, and herbal medicine through Pubmed. Results : The pathological basis for psoriasis is the action of inflammatory mediators by the activation of the immune response, which can be a cause of various cardiovascular, metabolic and psychological symptoms of psoriasis patients, in addition to skin lesions. The herbal medicines improve these inflammatory conditions and improve local lesions through herbal medicine such as Qingdai, which have a strong inhibitory effect on IL-17,22 production. Conclusions : Herbal medicines used in psoriasis are thought to be effective not only for the improvement of local psoriasis lesions through anti-inflammatory effect but also for the improvement of systemic inflammation associated with chronic low grade inflammation.
Keywords
Chronic Low Grade Inflammation; Systemic inflammation; Psoriasis; Herbal Medicine; Qingdai;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537-41.   DOI
2 Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol. 2007;57(2):347-54.   DOI
3 Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-35.   DOI
4 Heymann WR. Psoriasis: the heart of the matter. J Am Acad Dermatol. 2008;58(3):477-8.   DOI
5 Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573.
6 Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159(2):322-30.   DOI
7 Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115-26.   DOI
8 Fernandez-Sanchez A, Madrigal-Santillan E, Bautista M, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci. 2011; 12(5):3117-32.   DOI
9 McArdle MA, Finucane OM, Connaughton RM, et al. Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol (Lausanne). 2013;4:52.
10 Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200.   DOI
11 Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017;376(15):1492.
12 Liu C, Huang Y. Chinese Herbal Medicine on Cardiovascular Diseases and the Mechanisms of Action. Front Pharmacol. 2016;7:469.
13 Griffiths CE, Katsambas A, Dijkmans BA, Finlay AY, Ho VC, Johnston A, et al. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol. 2006;155 Suppl 2:1-16.
14 Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321-8.   DOI
15 Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32(6):982-6.   DOI
16 Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-7.   DOI
17 Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529-34.   DOI
18 Medzhitov R, Origin and physiological roles of inflammation. Nature. 2008; 454(7203):428-35.   DOI
19 Rainer H. Straub, Carsten Schradin. Chronic inflammatory systemic diseases: An evolutionary trade-off betweenacutely beneficial but chronically harmful programs, Evol Med Public Health. 2016;2016(1):37-51.
20 Netea MG, Balkwill F, Chonchol M, et al. A guiding map for inflammation. Nat Immunol. 2017;18(8):826-31.   DOI
21 Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.   DOI
22 Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-85.   DOI
23 Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205-12.   DOI
24 Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69:4-9.   DOI
25 Rousset L, Halioua B. Stress and psoriasis. Int J Dermatol. 2018;57(10):1165-172.   DOI
26 Zachariae R, Zachariae H, Blomqvist K, et al. Self-reportedstress reactivity and psoriasis-related stress of nordic psoriasissufferers. J Eur Acad Dermatol Venereol. 2004;18(1):27-36.   DOI
27 Song H, Fang F, Tomasson G, et al. Association of Stress-Related Disorders With Subsequent Autoimmune Disease. JAMA. 2018;319(23):2388-400.   DOI
28 Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2015;36(8):482-9c.   DOI
29 Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and metaanalysis of observational studies. Nutr Diabetes. 2012;2:e54.   DOI
30 Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J. 2016;7(6):471-80.   DOI
31 Reich K, The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26:3-11.   DOI
32 Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001; 103(13):1813-8.   DOI
33 Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004; 29(8):439-93.   DOI
34 Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA. 2006;295(12):1412-9.   DOI
35 Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159(2):322-30.   DOI
36 Correia B, Torres T. Obesity: a key component of psoriasis. Acta Biomed. 2015;86(2):121-9.
37 Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157(4):649-55.   DOI
38 Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin. 2015;33(1):41-55.   DOI
39 Naldi L, Peli L, Parazzini F. Association of Early-Stage Psoriasis With Smoking and Male Alcohol Consumption: evidence From an Italian Case-Control Study. Arch Dermatol. 1999;135(12):1479-84.
40 Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785-96.   DOI
41 Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.   DOI
42 Meng S, Lin Z, Wang Y, Wang Z, Li P, Zheng Y. Psoriasis therapy by Chinese medicine and modern agents. Chin Med. 2018;13:16.   DOI
43 Guan F, Lam W, Hu R, et al. Majority of Chinese Medicine Herb Category "Qing Re Yao" Have Multiple Mechanisms of Antiinflammatory Activity. Sci Rep. 2018;8(1):7416.   DOI
44 Cheng H-M, Wu Y-C, Wang Q, et al. Clinical efficacy and IL-17 targeting mechanism of Indigo naturalis as a topical agent in moderate psoriasis. BMC Complement Altern Med. 2017;17(1):439.   DOI
45 Vandevoorde V, Haegeman G, Fiers W. TNF-mediated IL6 gene expression and cytotoxicity are co-inducible in TNFresistant L929 cells. FEBS Lett. 1992;302(3):235-8.   DOI
46 De Sa DC, Festa Neto C. Inflammasomes and dermatology. An Bras Dermatol. 2016;91(5):566-78.   DOI
47 Tozser J, Benko S. Natural Compounds as Regulators of NLRP3 Inflammasome-Mediated IL-$1{\beta}$ Production. Mediators Inflamm. 2016;2016:5460302.
48 Lin X, Huang T, Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free Radic Res. 2016;50(6):585-95.   DOI
49 Wang D, Gu J, Zhu W, et al. PDTCM: a systems pharmacology platform of traditional Chinese medicine for psoriasis. Ann Med. 2017;49(8):652-60.   DOI
50 Hirayama A, Oowada S, Ito H, et al. Clinical significance of redox effects of Kampo formulae, a traditional Japanese herbal medicine: comprehensive estimation of multiple antioxidative activities. J Clin Biochem Nutr. 2018;62(1):39-48.
51 Wu M, Deng Y, Li S, et al. The Immunoregulatory Effects of Traditional Chinese Medicine on Psoriasis via its Action on Interleukin: Advances and Considerations. Am J Chin Med. 2018;46(4):739-50.   DOI
52 Lin YK, Chang YC, Hui RC, et al. A Chinese Herb, Indigo Naturalis, Extracted in Oil (Lindioil) Used Topically to Treat Psoriatic Nails: A Randomized Clinical Trial. JAMA Dermatol. 2015;151(6):672-4.   DOI
53 Yan Y, Liu W, Andres P, et al. Exploratory clinical trial to evaluate the efficacy of a topical traditional chinese herbal medicine in psoriasis vulgaris. Evid Based Complement Alternat Med. 2015;2015:719641.
54 Lin YK, See LC, Huang YH, Comparison of indirubin concentrations in indigo naturalis ointment for psoriasis treatment: a randomized, double-blind, dosage-controlled trial. Br J Dermatol. 2018;178(1):124-31.   DOI
55 Sun W, Gao Y, Yu X, et al. 'Psoriasis 1' reduces psoriasis-like skin inflammation by inhibiting the VDR-mediated nuclear NF-${\kappa}B$ and STAT signaling pathways. Mol Med Rep. 2018;18(3):2733-43.
56 Geng X, Shi H, Ye F, et al. Matrine inhibits itching by lowering the activity of calcium channel. Sci Rep. 2018;8(1):11328.   DOI
57 Lu C, Liu H, Jin X. Herbal Components of a Novel Formula PSORI-CM02 Interdependently Suppress Allograft Rejection and Induce CD8+CD122+PD-1+ Regulatory T Cells. Front Pharmacol. 2018;9:88.   DOI
58 Liu Q, Yin W, Han L, et al. Diarylheptanoid from rhizomes of Curcuma kwangsiensis (DCK) inhibited imiquimod-induced dendritic cells activation and Th1/Th17 differentiation. Int Immunopharmacol. 2018;56:339-48.   DOI
59 Parker S, Zhang CS, Yu JJ, et al. Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review. J Dermatolog Treat. 2017;28(1):21-31.   DOI
60 Zhang CS, Yang L, Zhang AL, et al. Is Oral Chinese Herbal Medicine Beneficial for Psoriasis Vulgaris? A Meta-Analysis of Comparisons with Acitretin. J Altern Complement Med. 2016;22(3):174-88.   DOI